Treatment of symptoms of seasonal or perennial allergic rhinitis in adults and children from 6 years of age. In patients with a history of moderate or severe symptoms of seasonal allergic rhinitis, the prophylactic use of the drug can be started up to 4 weeks prior to the anticipated beginning of the dusting period. Treatment of nasal polyposis symptoms in adults from 18 years of age.
Composition:
1 dose of nasal spray contains 50 μg of mometasone furoate. The suspension contains benzalkonium chloride (0.2 mg / g).
Action:
Contraindications:
Hypersensitivity components of the preparation. Current, untreated local infection, including nasal mucosa. Due to the inhibitory effect of glucocorticosteroids on wound healing, patients who have recently undergone nasal surgery or have recently had a history of nasal injury should not take glucocorticoids nasally until complete healing has been achieved.
Precautions:
Pregnancy and lactation:
Do not use during pregnancy (no tests). Newborns born by mothers who during their pregnancy received glucocorticoids should be carefully monitored for adrenal insufficiency. Do not use during breastfeeding unless the potential benefits to the mother justify a potential risk to the breast-fed baby.
Side effects:
Allergic rhinitis. Common: headache, nosebleeds, sore throat, burning, irritation or ulceration of the nasal mucosa. Polyposis of the nose. 200 μg twice daily - very common: nosebleed; often: throat irritation, headache; uncommon: upper respiratory tract infections. Dose 200 μg once a day - often: upper respiratory tract infections, nosebleed, headache. In addition, immediate-type hypersensitivity reactions (including bronchospasm, shortness of breath) may rarely occur during treatment. Very rarely: anaphylactic shock, angioneurotic edema, impaired taste and smell. Systemic effects of glucocorticoids may occur, especially when using high doses for a long time. In children receiving intranasal glucocorticoids, slow growth was reported at recorded doses.
Dosage:
Intranasally.Seasonal or all-season allergic rhinitis. Adults and children from 12 years: 2 aerosol sprays in each nostril once daily (total dose 200 μg). After controlling the symptoms reduce the dose to 1 spray into each nostril (total dose 100 μg); this dose should be effective in supportive treatment. If the symptoms are not sufficiently controlled, the dose may be increased to a maximum daily dose of 4 aerosol spray for each nostril once a day (total dose 400 μg). After improvement, a dose reduction is recommended. The onset of action was observed within 12 hours of the first dose, but the full effect of the preparation may not be obtained within the first 48 hours, therefore the preparation should be used regularly. Children 6-11 years: 1 spray into each nostril once a day (total dose 100 μg).Nasal polyps. Adults: The starting dose is 2 spray into each nostril once a day (total dose 200 μg). If after 5-6 weeks the symptoms do not decrease enough, the daily dose can be increased to 2 sprays for each nostril twice a day (total dose 400 μg). Dosage should then be reduced to the lowest dose that effectively controls symptoms. If there is no improvement after 5-6 weeks of using the product twice a day, another treatment should be considered. In the treatment of polyps, mometasone furoate was used for 4 months.
(C)
